Molecular Architecture of ADCs: Targets, Linkers, and Payloads

This webinar will explore:

Antibody targeting mechanisms
Linker technologies and their role in drug release
Payload selection and cytotoxic mechanism
How molecular design influences toxicity profiles
Patient selection criteria based on disease state and molecular targeting
The APP's role in managing patients on ADCs

This event was sponsored by Gilead, AstraZeneca, Astellas and Pfizer.

Amber B. Clemmons, PharmD, BCOP, FHOPA

Wellstar-MCG Health

Dr. Clemmons received her Doctor of Pharmacy degree from the University of Michigan College of Pharmacy, completed a University of Georgia College of Pharmacy Teaching Certificate during her PGY1 year at MCG Health/UGA, and PGY2 Hematology/Oncology Pharmacy residency at the University of North Carolina (UNC Hospitals and Clinics), Chapel Hill NC. She is currently a Clinical Professor at the University of Georgia College of Pharmacy and clinical pharmacy specialist for the adult bone marrow transplantation (BMT)/malignant hematology team at Wellstar-MCG Health. She is a highly active member of the Hematology Oncology Pharmacy Association (HOPA) and the American Society for Transplantation and Cellular Therapy (ASTCT) Pharmacy Special Interest Group (SIG), as well as a member of ASHP, GSHP, and the Georgia Cancer Center. Dr. Clemmons has received the ASTCT Pharmacy SIG New Practitioner of the Year Award (2014), Teacher of the Year Award at the UGA College of Pharmacy (2016), the HOPA New Practitioner Award (2017) and received HOPA fellow status (FHOPA) in 2022. Dr. Clemmons serves as the Residency Program Director for the UGA/Wellstar MCG Health Medical Center PGY2 Oncology Pharmacy program.